<?xml version="1.0" encoding="UTF-8"?>
<table xmlns="http://www.w3.org/1999/xhtml">
 <thead>
  <caption>PMC6507620</caption>
  <tr>
   <th>label</th>
   <th>caption</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>FIGURE 1</td>
   <td>Chemical structure of talinolol (TAL, M.W: 363.5, pKa: 9.4).</td>
  </tr>
  <tr>
   <td>FIGURE 2</td>
   <td>Typical physical appearance of the “Formulations” (F) and th ... </td>
  </tr>
  <tr>
   <td>FIGURE 3</td>
   <td>The effect of hydrophilic compositions on the particle size ... </td>
  </tr>
  <tr>
   <td>FIGURE 4</td>
   <td>Transmission electron microscopy (TEM) images of the droplet ... </td>
  </tr>
  <tr>
   <td>FIGURE 5</td>
   <td>In vitro release of TAL from the pure raw TAL powder, market ... </td>
  </tr>
  <tr>
   <td>FIGURE 6</td>
   <td>In vitro release of TAL from the pure raw TAL powder, market ... </td>
  </tr>
  <tr>
   <td>FIGURE 7</td>
   <td>The % TAL solubilized in aqueous phase (AP), pellet phase (P ... </td>
  </tr>
  <tr>
   <td>FIGURE 8</td>
   <td>Apparent permeability of TAL ( A: % cumulative drug concentr ... </td>
  </tr>
  <tr>
   <td>FIGURE 9</td>
   <td>In vitro toxicity test of pure TAL, Blank SNEDDS (drug free) ... </td>
  </tr>
  <tr>
   <td>FIGURE 10</td>
   <td>Plasma concentration– time profiles of TAL after a single or ... </td>
  </tr>
 </tbody>
</table>
